USD10
RGNX azioni
Informazioni su RegenxbioRegenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
USD10
RGNX azioni
Informazioni su RegenxbioRegenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
Statistiche
FINESTRA DI NEGOZIAZIONE
Chiusa
APRE ALLE
25 mar at 13:30 GMT+0
Capitalizzazione di mercato
403,10 Mln USD
PREZZO DI APERTURA
Dati insufficienti
MINIMO (1 anno)
5,04 USD
MASSIMO (1 anno)
16,19 USD
MINIMO (24H)
7,74 USD
MASSIMO (24 ore)
8,23 USD
VOLUME (24 ore)
281,00 USD
99,96%
Cronologia dei prezzi
Time | Price | Change |
|---|---|---|
Oggi | Dati insufficienti | Dati insufficienti |
1 giorno | 8,17 USD |